You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Impact of capsule endoscopy on management of inflammatory bowel disease: A single tertiary care center experience

Long, Millie D. MD, MPH1*; Barnes, Edward MD2; Isaacs, Kim MD, PhD1; Morgan, Douglas MD, MPH1; Herfarth, Hans H. MD, PhD1

Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21571
Original Clinical Articles
Abstract

Background:: Capsule endoscopy (CE) is performed to assess inflammatory bowel disease (IBD). We aimed to define the results of CE in subtypes of IBD and to determine whether CE results in management changes.

Methods:: A retrospective cohort study was performed of all CEs for IBD at a tertiary care center from 2003–2009. Descriptive statistics were used to compare IBD‐specific medications, surgeries, and imaging studies in the 3 months prior and 3 months after CE.

Results:: Of 907 CEs performed from 2003–2009, 128 were for an indication of symptomatic IBD and 124 capsules left the stomach (86 for Crohn's disease [CD], 15 for indeterminate colitis [IC], 23 for pouchitis). Only 22.1% of CEs done for CD were normal, as compared to 53.3% for IC and 34.8% for pouchitis. Severe findings in CD consisted of multiple aphthae/ulcers (22.1%), stenosis (8.1%), and stenosis with immediate retention (17.4%). In CD, 61.6% had a change in medication in the 3 months after the CE, with 39.5% initiating a new IBD medication, most commonly budesonide or corticosteroids. In the 3 months following CE, 12.8% of patients with CD underwent surgery. Severe findings on CE in patients with CD, as compared to no/minimal findings, resulted in significant differences in medication changes (73.2% versus 51.1%, P = 0.04), addition of medications (58.5% versus 22.2%, P < 0.01), and surgeries (21.9% versus 4.4%, P = 0.01).

Conclusions:: CE results in management changes in the majority of cases of symptomatic IBD, regardless of the subtype of IBD. (Inflamm Bowel Dis 2011;)

Author Information

1University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, North Carolina

2University of North Carolina at Chapel Hill, Department of Medicine, Chapel Hill, North Carolina

*Reprints: UNC‐CH, CB #7080, Chapel Hill, NC 27599‐7080

Email: millie_long@med.unc.edu

Received 9 September 2010; Accepted 11 October 2010

Published online 6 January 2011 in Wiley Online Library (wileyonlinelibrary.com).

Supported, in part, by grants from the National Institutes of Health (NIH) (T32 DK007634, P30 DK034987), a junior faculty career development award, and a senior research award from the Crohn's and Colitis Foundation of America.

Dr. Douglas Morgan has received Training Course honoraria from Given Imaging.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.